About

Striving to improve
human health

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives. Our approach combines our leading expertise in protein kinases with sound execution and an intense focus on discovery.

In addition to a diverse and growing portfolio of research programs, we are moving multiple investigational medicines through clinical development for patients with a broad range of genomically defined cancers and rare diseases.

Leveraging proven cancer drug targets

Protein kinases (enzymes that modify the functions of proteins) are critical to controlling biochemical pathways and are involved in many hallmarks of tumor biology – yet currently approved drugs focus on less than 5% of known kinases.

Thinking in giant leaps

Impatient with the status quo, our passion for innovation drives us forward. We aim to connect the worlds of drug discovery, clinical development and commercialization to deliver a new generation of potent, selective medicines.

A uniquely targeted, scalable approach

By focusing on genomic drivers of disease, we aim to identify the people most likely to respond to our therapies, increase efficiency during clinical development and ultimately deliver truly transformational therapies to patients.
“Patients need treatments that can provide meaningful, lasting benefit. By targeting genomic drivers of disease, we believe we can get the right drugs to the right patients.”
Andy Boral, M.D., Ph.D., Chief Medical Officer